Literature DB >> 6807231

Rocky Mountain spotless fever: a dilemma for the clinician.

E L Westerman.   

Abstract

Failure of the characteristic rash to develop during the course of illness in Rocky Mountain spotted fever may lead to the delay or failure of diagnosis and may result in fetal encephalopathic illness with disseminated vascular injury. Four patients are described herein in whom a rash failed to develop and the diagnosis was initially incorrect. Each patient was seen at least once before hospital admission by a physician and given ineffective antibiotic therapy, resulting in fatal complications. Besides the failure of the rash to develop, the lack of any specific diagnostic test that is useful during the acute illness represents a major difficulty for the physician in making the diagnosis before the patient's death. Any adult in an endemic geographic area who is initially seen with an undifferentiated acute febrile illness in which headache and myalgias are prominent should be considered for treatment with tetracycline unless otherwise contraindicated.

Entities:  

Mesh:

Year:  1982        PMID: 6807231

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  Antimicrobial therapy of rickettsial diseases.

Authors:  D Raoult; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 2.  Rocky Mountain spotted fever: a disease in need of microbiological concern.

Authors:  D H Walker
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

3.  Successful treatment of Rocky Mountain 'spotless' fever.

Authors:  P G Ramsey; O W Press
Journal:  West J Med       Date:  1984-01

4.  Risk factors for fatal outcome from rocky mountain spotted Fever in a highly endemic area-Arizona, 2002-2011.

Authors:  Joanna J Regan; Marc S Traeger; Dwight Humpherys; Dianna L Mahoney; Michelle Martinez; Ginny L Emerson; Danielle M Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Velda Williams; Charlene Hamilton; Craig Levy; Ken Komatsu; David A Yost; Jennifer H McQuiston
Journal:  Clin Infect Dis       Date:  2015-02-19       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.